Lowest Price Guaranteed From USD 5,899
Published
February 2023
Pages
232
View Count
20684
Example Insights
 |
 |
 |
 |
 |
Report Description
The process of drug development, beginning from the discovery of a molecule to its commercial launch, takes around 10-15 years and capital investments worth USD 4-10 billion. It is a well-known fact that only a small proportion of molecules, which are selected for further investigation during the initial stages of research, are actually translated into product candidates. Given the complexities involved in the drug discovery process, the overall research and development (R&D) expenditure in the pharmaceutical / biotechnology sector has steadily increased over time. The industry is presently under tremendous pressure to identify different ways to mitigate the risks of failure of drug discovery programs and meet expectations of the growing patient population.
DNA-encoded libraries (also known as DELs), owing to their advantages (such as library size, cost and equipment needs) over high-throughput screening, have demonstrated to be a sophisticated combinatorial drug discovery tool for the synthesis and screening of large collections of small molecule compounds. Interestingly, DNA-encoded libraries encompassing as high as 40 trillion different molecules have been developed, enabling screening, hit identification and discovery of pharmacological leads (including macrocycles, natural products and small molecules) against undruggable and unique targets using a single library and accelerating the process of drug development. Moreover, introduction of automated screening of small organic ligands using DNA-encoded chemical libraries has enabled identification of potential lead molecules within a time duration of just few days.
The DNA-Encoded Libraries: Platforms and Services Market (2nd Edition): Industry Trends and Global Forecasts, 2023-2035 [upcoming report] features an extensive study of the current market landscape and future opportunity for the players involved in the field of DNA-encoded libraries. The report answers many key questions related to this domain.
DNA-encoded libraries are considered highly effective for the discovery of small-molecule protein ligands. These compound collections consist of small molecules covalently connected to individual sequences carrying readable information about the compound structure. In addition, DEL technology enables efficient synthesis, handling, and interrogation of vast number of chemically synthesized, drug-like compounds. Moreover, with the help of artificial intelligence and machine learning tools, this process can be streamlined even further by employing algorithms to navigate through these enormous datasets, predict the best drug compounds and even design subsequent experiments to increase the likelihood of clinic success.
Traditional methods used for screening hits / lead molecules require lot of resources as compounds are tested individually, making it a time consuming process that usually takes several months to complete. On the other hand, the use of DELs facilitate the development and optimization of new drug compounds within few days. In addition, DELs aid in the generation of valuable data related to their structure and interactions with different biological molecules.
Presently, more than 40 companies are offering services related to DNA-encoded libraries for the purpose of drug discovery. Majority of the encoded libraries are designed to identify leads against protein pump inhibitors, which are otherwise difficult to screen using traditional libraries. However, in terms of the type of pharmacological leads, majority of the libraries are designed for the discovery of small molecules.
The DNA-encoded library market is projected to grow at a sustainable pace in the coming years. Currently, the market is likely to be driven by two business models; the first involves out-licensing of proprietary library platforms to interested clients and the second involves charging fee-for-service to conduct research using their libraries.
Scope of the Report
The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies. Amongst other elements, the report includes:
The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Drug Development
3.3. Drug Discovery Process
3.3.1. Target Identification
3.3.2. Target Validation
3.3.3. Hit Generation
3.3.3.1. High-Throughput Screening
3.3.3.2. Fragment Based Screening
3.3.3.3. Virtual Screening
3.3.3.4. DNA-Encoded Library-based Screening
3.3.4. Hit-to-Lead
3.3.5. Lead Optimization
3.4. Overview of DNA-Encoded Libraries
3.4.1. Historical Evolution
3.4.2. Encoding Strategies for Library Construction
3.4.3. Comparison of Traditional Libraries and DNA-Encoded Libraries
3.4.4. Key Advantages
3.4.5. Challenges and Limitations
3.5. Future Perspectives and Opportunity Areas
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. DNA-Encoded Libraries: Overall Market Landscape
4.2.1. Analysis by Library Size
4.2.2. Analysis by Method of Library Synthesis
4.2.3. Analysis by Type of Pharmacological Lead
4.2.4. Analysis by Therapeutic Target
4.2.5. Analysis by Therapeutic Area
4.3. DNA-Encoded Libraries: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Type of Service Offered
4.3.4. Analysis by Geographical Location
4.4. DNA-Encoded Libraries: Supporting Companies
5. PARTNERSHIPS AND COLLABORATIONS
5.1. Chapter Overview
5.2. Partnership Models
5.3. DNA-Encoded Libraries: Recent Partnerships and Collaborations
5.3.1. Analysis by Year of Partnership
5.3.2. Analysis by Type of Partnership
5.3.3. Analysis by Year of Partnership and Type of Partner
5.3.4 Most Active Players: Analysis by Number of Partnerships
5.3.5. Most Popular DNA-Encoded Libraries: Analysis by Number of Partnerships
5.3.6. Regional Analysis
5.3.6.1. Most Active Players: Analysis by Local and International Agreements
5.3.6.2. Intercontinental and Intracontinental Agreements
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. HitGen
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.2.1. HitGen’s DNA-Encoded Libraries
6.2.3. Recent Developments and Future Outlook
6.3. X-Chem
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.2.1. X-Chem’s DNA-Encoded Libraries
6.3.3. Recent Developments and Future Outlook
6.4. Vipergen
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.2.1. Vipergen’s DNA-Encoded Libraries
6.4.3. Recent Developments and Future Outlook
6.5. DyNAbind
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.2.1. DyNAbind’s DNA-Encoded Libraries
6.5.3. Recent Developments and Future Outlook
7. CASE STUDY: LIKELY BIOLOGICAL TARGETS FOR DRUG DISCOVERY USING DNA-ENCODED LIBRARIES
7.1. Chapter Overview
7.2. Undruggable Cancer Targets
7.2.1. G protein-coupled receptors (GPCRs): Overview
7.2.2. GPCRs Targeting Drugs: List of Clinical / Preclinical Molecules
7.3. DNA Repair Targets
7.3.1. poly ADP ribose polymerase (PARP) Inhibitors: Overview
7.2.2. PARP Inhibitors: List of Clinical / Preclinical Molecules
7.4. Other Targets
8. BIG PHARMA INITIATIVES: DNA-ENCODED LIBRARIES
8.1. Chapter Overview
8.2. Top Pharmaceutical Companies
8.3. Amgen
8.3.1. Company Snapshot
8.3.2. Initiatives by Amgen
8.4. Astra Zeneca
8.4.1. Company Snapshot
8.4.2. Initiatives by AstraZeneca
8.5. GSK
8.5.1. Company Snapshot
8.5.2. Initiatives by GSK
8.6. Novartis
8.6.1. Company Snapshot
8.6.2. Initiatives by Novartis
8.7. Pfizer
8.7.1. Company Snapshot
8.7.2. Initiatives by Pfizer
8.8. Roche
8.8.1. Company Snapshot
8.8.2. Initiatives by Roche
9. DNA-ENCODED LIBRARY MARKET: OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Input Data
9.3. Forecast Methodology
9.4. DNA-Encoded Libraries Licensing Market: Upfront and Milestone Payments, 2023, 2028 And 2035
9.5. DNA-Encoded Libraries Market: Additional Opportunity
10. CONCLUDING REMARKS
10.1. Chapter Overview
10.2. Key Takeaways
11. INTERVIEW TRANSCRIPTS
12. APPENDIX 1: TABULATED DATA
13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Drug Discovery and Development Timeline
Figure 3.2 Drug Discovery Process
Figure 3.3 Constructing a DNA-Encoded Library
Figure 3.4 Historical Evolution of DNA-Encoded Libraries
Figure 3.5 Encoding Strategies for Constructing DNA-Encoded Libraries
Figure 3.6 Comparison of Traditional Libraries and DNA-Encoded Libraries
Figure 3.7 Advantages of DNA-Encoded Libraries
Figure 3.8 Limitations of DNA-Encoded Libraries
Figure 4.1. DNA-Encoded Libraries: Distribution by Library Size
Figure 4.2. DNA-Encoded Libraries: Distribution by Type of Pharmacological Lead
Figure 4.3. DNA-Encoded Libraries: Distribution by Method of Library Synthesis
Figure 4.4. DNA-Encoded Libraries: Distribution by Therapeutic Target
Figure 4.5. DNA-Encoded Libraries: Distribution by Therapeutic Area
Figure 4.6. DNA-Encoded Libraries: Distribution by Year of Establishment
Figure 4.7. DNA-Encoded Libraries: Distribution by Company Size
Figure 4.8. DNA-Encoded Libraries: Distribution by Geographical Location
Figure 4.9. DNA-Encoded Libraries: Distribution by Year of Establishment, Company Size and Geographical Location
Figure 4.10. DNA-Encoded Libraries: Distribution by Type of Service Offered
Figure 4.11. DNA-Encoded Libraries: Geographical Landscape of Developers by Type of Service Offering
Figure 5.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2010-2023 (till February)
Figure 5.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 5.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Figure 5.4 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 5.5 Most Active Players: Distribution by Number of Partnerships
Figure 5.6 Most Popular Technologies: Distribution by Number of Partnerships
Figure 5.7 Most Active Players: Geographical Distribution by Number of Partnerships
Figure 5.8 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 6.1 HitGen: Service Portfolio
Figure 6.2 HitGen: DNA-Encoded Library Synthesis
Figure 6.3 HitGen: DNA-Encoded Library Steps
Figure 6.4 X-Chem: DNA-Encoded Library Synthesis
Figure 6.5 Vipergen: Service Portfolio
Figure 6.6 Vipergen: DNA-Encoded Library Synthesis
Figure 6.7 Vipergen: MedChem HTS versus YoctoReactor
Figure 6.8 DyNAbind: Service Portfolio
Figure 6.9 DyNAbind: Binding Profiler Validation
Figure 7.1 Difficult-to-Modulate Cancer Targets: Transcription Factors
Figure 7.2 PARP Proteins: Mechanism of Action
Figure 8.1 Big Pharma Players: Heat Map Analysis of Top Pharmaceutical Companies
Figure 9.1 Licensing Agreements: Distribution of Financial Components
Figure 9.2 Library Licensing Deal: Payment Structure
Figure 9.3 DNA-Encoded Libraries: Platforms and Services Market: Upfront and Milestone Payments, 2023, 2028 and 2035 (USD Million)
Figure 9.4 Case Study: Popular Drug Discovery Methods
Table 4.1. DNA-Encoded Libraries: Technology Overview
Table 4.2. DNA-Encoded Libraries: Methods of Library Synthesis
Table 4.3. DNA-Encoded Libraries: Developer Overview
Table 4.4. DNA-Encoded Libraries: Type of Service Offered
Table 4.5. DNA-Encoded Libraries: Supporting Companies
Table 5.1 DNA-Encoded Libraries: List of Partnerships, 2010-2019
Table 5.2 Most Active Players: Distribution by Number of Partnerships
Table 6.1 DNA-Encoded Libraries: List of Companies Profiles
Table 6.2 HitGen: Company Snapshot
Table 6.3 HitGen: Recent Developments and Future Outlook
Table 6.4 X-Chem: Company Snapshot
Table 6.5 X-Chem: Recent Developments and Future Outlook
Table 6.6 Vipergen: Company Snapshot
Table 6.7 Vipergen: Recent Developments and Future Outlook
Table 6.8 DyNAbind: Company Snapshot
Table 6.9 DyNAbind: Recent Developments and Future Outlook
Table 7.1 GPCR’s: List of Clinical / Preclinical Molecules
Table 7.2 PARP Inhibitors: List of Clinical / Preclinical Molecules
Table 8.1 Amgen: Company Snapshot
Table 8.2 AstraZeneca: Company Snapshot
Table 8.3 GSK: Company Snapshot
Table 8.4 Novartis: Company Snapshot
Table 8.5 Pfizer: Company Snapshot
Table 8.6 Roche: Company Snapshot
Table 9.1 Library Licensing Deal: Tranches of Milestone Payments
Table 9.2 DNA-Encoded Libraries: Average Upfront Payments and Average Milestone Payments (USD Million)
Table 10.1 DNA-Encoded Libraries: Summary of the Competitive Insights
Table 12.1 DNA-Encoded Libraries: Distribution by Library Size
Table 12.2 DNA-Encoded Libraries: Distribution by Type of Pharmacological Lead
Table 12.3 DNA-Encoded Libraries: Distribution by Method of Library Synthesis
Table 12.4 DNA-Encoded Libraries: Distribution by Therapeutic Target
Table 12.5 DNA-Encoded Libraries: Distribution by Therapeutic Area
Table 12.6 DNA-Encoded Libraries: Distribution by Year of Establishment
Table 12.7 DNA-Encoded Libraries: Distribution by Company Size
Table 12.8 DNA-Encoded Libraries: Distribution by Geographical Location
Table 12.9 DNA-Encoded Libraries: Distribution by Type of Service Offered
Table 12.10 Partnerships and Collaborations: Cumulative Year-wise Trend, 2010-2023 (till February)
Table 12.11 Partnerships and Collaborations: Distribution by Type of Partnership
Table 12.12 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Table 12.13 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 12.14 Partnerships and Collaborations: Most Active Players
Table 12.15 Most Popular Technologies: Distribution by Number of Partnerships
Table 12.16 Partnerships and Collaborations: Analysis by Local and International Distribution
Table 12.17 DNA-encoded Libraries: Platforms and Services Market: Upfront and Milestone Payments, 2023, 2028 and 2035 (USD Million)
Table 12.18 Case Study: Popular Drug Discovery Methods
The following companies and organizations have been mentioned in the report:
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES